Please use this identifier to cite or link to this item: https://doi.org/10.1038/ncomms13131
Title: Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets
Authors: Chen, Y.-B
Xu, J
Skanderup, A.J 
Dong, Y
Brannon, A.R
Wang, L
Won, H.H
Wang, P.I
Nanjangud, G.J
Jungbluth, A.A
Li, W
Ojeda, V
Hakimi, A.A
Voss, M.H
Schultz, N
Motzer, R.J
Russo, P
Cheng, E.H
Giancotti, F.G
Lee, W
Berger, M.F
Tickoo, S.K
Reuter, V.E
Hsieh, J.J
Keywords: BAP1 protein
DNA
KMT2C protein
mammalian target of rapamycin
mammalian target of rapamycin complex 1
merlin
oncoprotein
phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase
RNA
SETD2 protein
TSC1 protein
tuberin
unclassified drug
BAP1 protein, human
histone lysine methyltransferase
MTOR protein, human
Set2 protein, human
target of rapamycin kinase
tumor protein
tumor suppressor protein
ubiquitin thiolesterase
bioassay
cancer
cells and cell components
gene expression
genetic analysis
genetic marker
histology
molecular analysis
mutation
protein
tumor
Article
cancer genetics
cancer survival
carcinogenesis
cell assay
chromatin
clinical outcome
controlled study
DNA damage
fluorescence in situ hybridization
gene expression
germline mutation
histology
human
human cell
human tissue
immunohistochemistry
kidney carcinoma
molecular genetics
nucleotide sequence
RNA sequence
signal transduction
single nucleotide polymorphism
somatic mutation
tumor gene
genetics
HEK293 cell line
kidney tumor
neurofibromatosis type 2
pathology
renal cell carcinoma
tumor cell line
Carcinoma, Renal Cell
Cell Line, Tumor
DNA Damage
HEK293 Cells
Histone-Lysine N-Methyltransferase
Humans
In Situ Hybridization, Fluorescence
Kidney Neoplasms
Neoplasm Proteins
Neurofibromatosis 2
Polymorphism, Single Nucleotide
Signal Transduction
TOR Serine-Threonine Kinases
Tumor Suppressor Proteins
Ubiquitin Thiolesterase
Issue Date: 2016
Publisher: Nature Publishing Group
Citation: Chen, Y.-B, Xu, J, Skanderup, A.J, Dong, Y, Brannon, A.R, Wang, L, Won, H.H, Wang, P.I, Nanjangud, G.J, Jungbluth, A.A, Li, W, Ojeda, V, Hakimi, A.A, Voss, M.H, Schultz, N, Motzer, R.J, Russo, P, Cheng, E.H, Giancotti, F.G, Lee, W, Berger, M.F, Tickoo, S.K, Reuter, V.E, Hsieh, J.J (2016). Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nature Communications 7 : 13131. ScholarBank@NUS Repository. https://doi.org/10.1038/ncomms13131
Rights: Attribution 4.0 International
Abstract: Renal cell carcinomas with unclassified histology (uRCC) constitute a significant portion of aggressive non-clear cell renal cell carcinomas that have no standard therapy. The oncogenic drivers in these tumours are unknown. Here we perform a molecular analysis of 62 high-grade primary uRCC, incorporating targeted cancer gene sequencing, RNA sequencing, single-nucleotide polymorphism array, fluorescence in situ hybridization, immunohistochemistry and cell-based assays. We identify recurrent somatic mutations in 29 genes, including NF2 (18%), SETD2 (18%), BAP1 (13%), KMT2C (10%) and MTOR (8%). Integrated analysis reveals a subset of 26% uRCC characterized by NF2 loss, dysregulated Hippo-YAP pathway and worse survival, whereas 21% uRCC with mutations of MTOR, TSC1, TSC2 or PTEN and hyperactive mTORC1 signalling are associated with better clinical outcome. FH deficiency (6%), chromatin/DNA damage regulator mutations (21%) and ALK translocation (2%) distinguish additional cases. Altogether, this study reveals distinct molecular subsets for 76% of our uRCC cohort, which could have diagnostic and therapeutic implications. © The Author(s) 2016.
Source Title: Nature Communications
URI: https://scholarbank.nus.edu.sg/handle/10635/179799
ISSN: 2041-1723
DOI: 10.1038/ncomms13131
Rights: Attribution 4.0 International
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1038_ncomms13131.pdf897.11 kBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons